Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 38
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1851 | PENN ENGINEERING MANUFACTURING | 8 | 00% | 2 | 6 | 2022–2024 |
| 1852 | PEPTIDREAM | 8 | 112.5% | 0 | 7 | 2022–2026 |
| 1853 | PERSTORP | 8 | 112.5% | 0 | 7 | 2022–2026 |
| 1854 | PETRA PHARMA | 8 | 00% | 0 | 8 | 2022–2025 |
| 1855 | PHANES THERAPEUTICS | 8 | 112.5% | 0 | 7 | 2020–2025 |
| 1856 | PHOENIX ELECTRIC | 8 | 225% | 3 | 3 | 2022–2023 |
| 1857 | PLANTICS HOLDING | 8 | 112.5% | 0 | 7 | 2022–2025 |
| 1858 | PLEXIUM | 8 | 112.5% | 0 | 7 | 2020–2026 |
| 1859 | PROTAGONIST THERAPEUTICS | 8 | 00% | 2 | 6 | 2022–2025 |
| 1860 | PURATOS | 8 | 00% | 1 | 7 | 2022–2025 |
| 1861 | QLAR EUROPE | 8 | 112.5% | 0 | 7 | 2023–2026 |
| 1862 | RE TECHNOLOGIES | 8 | 00% | 0 | 8 | 2023–2024 |
| 1863 | RIO TINTO ALCAN INTERNATIONAL | 8 | 225% | 0 | 6 | 2021–2026 |
| 1864 | ROLLOMATIC | 8 | 00% | 0 | 8 | 2024–2026 |
| 1865 | S D SIGHT DIAGNOSTICS | 8 | 00% | 1 | 7 | 2022–2025 |
| 1866 | SACMI IMOLA S C | 8 | 00% | 0 | 8 | 2022–2025 |
| 1867 | SANDVIK MINING AND CONSTRUCTION AUSTRALIA PRODUCTION SUPPLY PTY | 8 | 112.5% | 1 | 6 | 2022–2025 |
| 1868 | SANYO ELECTRIC | 8 | 787.5% | 0 | 1 | 2021–2023 |
| 1869 | SCANCELL | 8 | 00% | 0 | 8 | 2022–2026 |
| 1870 | SCHUNK SONOSYSTEMS | 8 | 450% | 0 | 4 | 2022–2025 |
| 1871 | SCORPION THERAPEUTICS | 8 | 00% | 0 | 8 | 2023–2026 |
| 1872 | SCRIBE THERAPEUTICS | 8 | 00% | 0 | 8 | 2022–2025 |
| 1873 | SEMTECH | 8 | 225% | 2 | 4 | 2022–2025 |
| 1874 | SHAW INDUSTRIES GROUP | 8 | 00% | 0 | 8 | 2022–2025 |
| 1875 | SHENZHEN YHLO BIOTECH | 8 | 450% | 0 | 4 | 2022–2023 |
| 1876 | SHINE TECHNOLOGIES | 8 | 00% | 0 | 8 | 2023–2026 |
| 1877 | SHIONOGI | 8 | 112.5% | 1 | 6 | 2022–2026 |
| 1878 | SITRYX THERAPEUTICS | 8 | 112.5% | 0 | 7 | 2022–2026 |
| 1879 | SKYDIO | 8 | 00% | 0 | 8 | 2023–2026 |
| 1880 | SLATE TECHNOLOGIES | 8 | 00% | 0 | 8 | 2024–2026 |
| 1881 | SLAYBACK PHARMA | 8 | 00% | 1 | 7 | 2022–2023 |
| 1882 | SPARQ SYSTEMS | 8 | 00% | 0 | 8 | 2023–2025 |
| 1883 | SPOGEN BIOTECH | 8 | 00% | 0 | 8 | 2024–2025 |
| 1884 | STAHL INTERNATIONAL | 8 | 225% | 0 | 6 | 2022–2025 |
| 1885 | STORA ENSO | 8 | 112.5% | 0 | 7 | 2022–2026 |
| 1886 | SUMIDA | 8 | 112.5% | 0 | 7 | 2022–2026 |
| 1887 | SUNCOKE TECHNOLOGY AND DEVELOPMENT | 8 | 112.5% | 0 | 7 | 2017–2026 |
| 1888 | SUTRO BIOPHARMA | 8 | 00% | 0 | 8 | 2022–2026 |
| 1889 | SUZHOU MAXWELL TECHNOLOGIES | 8 | 00% | 0 | 8 | 2024–2026 |
| 1890 | TAVACI TECHNOLOGIES | 8 | 00% | 0 | 8 | 2026–2026 |
| 1891 | TDK TAIWAN | 8 | 337.5% | 0 | 5 | 2020–2024 |
| 1892 | TECHNOLOGICAL RESOURCES PTY | 8 | 00% | 0 | 8 | 2022–2026 |
| 1893 | TERNS PHARMACEUTICALS | 8 | 00% | 3 | 5 | 2022–2026 |
| 1894 | TERUMO BCT | 8 | 00% | 0 | 8 | 2024–2025 |
| 1895 | THALES DIS FRANCE | 8 | 112.5% | 0 | 7 | 2022–2026 |
| 1896 | THALES MANAGEMENT SERVICES DEUTSCHLAND | 8 | 337.5% | 0 | 5 | 2022–2022 |
| 1897 | THE BOOTS | 8 | 00% | 3 | 5 | 2022–2024 |
| 1898 | THE HERSHEY | 8 | 00% | 1 | 7 | 2022–2024 |
| 1899 | THE HOSPITAL FOR SICK CHILDREN | 8 | 00% | 0 | 8 | 2022–2024 |
| 1900 | THE JACKSON LABORATORY | 8 | 00% | 0 | 8 | 2023–2026 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →